#1582
Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction:
Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Authors:
Miki M,
Ito T,
Hijioka M,
Kawabe K,
Jensen R,
Keywords:
Pancreatic neuroendocrine tumors,
Chromogranin A,
Chromogranin B,
#693
Histopathological Reporting of Neuroendocrine Tumors: A 4-Year Tertiary Referral Centre Experience
Introduction:
Histopathological recognition of neuroendocrine tumors (NETs) is straightforward, however, sub-classification, grading and staging is challenging with frequently evolving pathological criteria.
Conference:
10th Annual ENETSConcerence (2013)
Presenting Author:
Authors:
Karpathakis A,
Miki Y,
Thirlwell C,
Meyer T,
Toumpanakis C,
Keywords:
histopathology,
Ki-67,
staging,
#38
Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction:
Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Sasano H
Authors:
Iida S,
Miki Y,
Ono K,
Sasano H,
Keywords:
neuroendocrine tumors,
mTOR inhibitors,
MEK inhibitors,
combination therapy,
